Mabpharm Limited (HKG:2181)

Mabpharm Statistics

Total Valuation

Mabpharm has a market cap or net worth of HKD 1.98 billion. The enterprise value is 2.22 billion.

Market Cap	1.98B
Enterprise Value	2.22B

Important Dates

The next estimated earnings date is Thursday, May 28, 2026.

Earnings Date	May 28, 2026
Ex-Dividend Date	n/a

Share Statistics

Mabpharm has 4.12 billion shares outstanding.

Current Share Class	4.12B
Shares Outstanding	4.12B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	49.95%
Owned by Institutions (%)	0.00%
Float	941.30M

Valuation Ratios

The trailing PE ratio is 43.13.

PE Ratio	43.13
Forward PE	n/a
PS Ratio	2.75
PB Ratio	11.31
P/TBV Ratio	11.31
P/FCF Ratio	44.81
P/OCF Ratio	22.02
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 30.91, with an EV/FCF ratio of 50.29.

EV / Earnings	34.94
EV / Sales	3.09
EV / EBITDA	30.91
EV / EBIT	n/a
EV / FCF	50.29

Financial Position

The company has a current ratio of 0.81, with a Debt / Equity ratio of 2.08.

Current Ratio	0.81
Quick Ratio	0.50
Debt / Equity	2.08
Debt / EBITDA	5.06
Debt / FCF	8.23
Interest Coverage	0.44

Financial Efficiency

Return on equity (ROE) is 46.40% and return on invested capital (ROIC) is 0.68%.

Return on Equity (ROE)	46.40%
Return on Assets (ROA)	0.28%
Return on Invested Capital (ROIC)	0.68%
Return on Capital Employed (ROCE)	0.78%
Weighted Average Cost of Capital (WACC)	6.81%
Revenue Per Employee	1.85M
Profits Per Employee	163,440
Employee Count	383
Asset Turnover	0.60
Inventory Turnover	0.59

Taxes

Income Tax	-58.95M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.63% in the last 52 weeks. The beta is 0.61, so Mabpharm's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	+11.63%
50-Day Moving Average	0.48
200-Day Moving Average	0.57
Relative Strength Index (RSI)	52.54
Average Volume (20 Days)	334,900

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mabpharm had revenue of HKD 718.98 million and earned 63.58 million in profits. Earnings per share was 0.01.

Revenue	718.98M
Gross Profit	638.36M
Operating Income	5.34M
Pretax Income	4.63M
Net Income	63.58M
EBITDA	65.96M
EBIT	5.34M
Earnings Per Share (EPS)	0.01

Balance Sheet

The company has 121.58 million in cash and 363.60 million in debt, with a net cash position of -242.02 million or -0.06 per share.

Cash & Cash Equivalents	121.58M
Total Debt	363.60M
Net Cash	-242.02M
Net Cash Per Share	-0.06
Equity (Book Value)	175.05M
Book Value Per Share	0.04
Working Capital	-111.00M

Cash Flow

In the last 12 months, operating cash flow was 89.90 million and capital expenditures -45.72 million, giving a free cash flow of 44.17 million.

Operating Cash Flow	89.90M
Capital Expenditures	-45.72M
Depreciation & Amortization	62.72M
Net Borrowing	10.91M
Free Cash Flow	44.17M
FCF Per Share	0.01

Margins

Gross margin is 88.79%, with operating and profit margins of 0.74% and 8.84%.

Gross Margin	88.79%
Operating Margin	0.74%
Pretax Margin	0.64%
Profit Margin	8.84%
EBITDA Margin	9.17%
EBIT Margin	0.74%
FCF Margin	6.14%

Dividends & Yields

Mabpharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	3.21%
FCF Yield	2.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mabpharm has an Altman Z-Score of 0.07 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.07
Piotroski F-Score	7